Idiopathic Pulmonary Fibrosis Market by Drug Type, Distribution Channel, End-User

List of Tables

The Idiopathic Pulmonary Fibrosis Market is projected to reach USD 5.03 billion by 2030 from USD 3.29 billion in 2022, at a CAGR of 5.43% during the forecast period.

Global Idiopathic Pulmonary Fibrosis Market

KEY MARKET STATISTICS
Base Year Value [2022]	USD 3.29 billion
Estimated Year Value [2023]	USD 3.46 billion
Forecast Year Value [2030]	USD 5.03 billion
CAGR (%)	5.43%

Idiopathic Pulmonary Fibrosis Market - IMG1

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Idiopathic Pulmonary Fibrosis Market.

Based on Drug Type, market is studied across Nintedanib and Pirfenidone. The Pirfenidone is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Offline and Online. The Offline is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Ambulatory Surgical Centers, Home Care Facilities, and Hospitals & Clinics. The Hospitals & Clinics is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Idiopathic Pulmonary Fibrosis Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Idiopathic Pulmonary Fibrosis Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Idiopathic Pulmonary Fibrosis Market, highlighting leading vendors and their innovative profiles. These include Algernon Pharmaceuticals Inc., Alkem Laboratories Ltd., AstraZeneca PLC, Avalyn Pharma Inc., Biogen, Inc., Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Camber Pharmaceuticals, Inc. by Hetero Labs Limited, Chemo Healthcare Pvt. Ltd., Cipla Limited, Dr Reddy's Laboratories Ltd., FibroGen, Inc., Galapagos NV, Glenmark Pharmaceuticals Ltd., GNI Group Ltd., Horizon Therapeutics PLC by Amgen Inc., Lupin Ltd., MediciNova, Inc., Merck & Co., Mission Therapeutics, MSN Laboratories Private Limited, Sandoz International GmbH, Sanify Healthcare Private Limited, Shionogi & Co., Ltd., and Teva Pharmaceuticals, Inc..

The report offers valuable insights on the following aspects:

1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.

2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.

3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.

4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.

5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast for the Idiopathic Pulmonary Fibrosis Market?

2. Which products, segments, applications, and areas hold the highest investment potential in the Idiopathic Pulmonary Fibrosis Market?

3. What is the competitive strategic window for identifying opportunities in the Idiopathic Pulmonary Fibrosis Market?

4. What are the latest technology trends and regulatory frameworks in the Idiopathic Pulmonary Fibrosis Market?

5. What is the market share of the leading vendors in the Idiopathic Pulmonary Fibrosis Market?

6. Which modes and strategic moves are suitable for entering the Idiopathic Pulmonary Fibrosis Market?

Product Code: MRR-2A0283E2563D

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Idiopathic Pulmonary Fibrosis Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising prevalence of idiopathic pulmonary fibrosis
  - 5.1.1.2. Advancements in the medical and diagnostic technology
- 5.1.2. Restraints
  - 5.1.2.1. High cost of therapies and treatments
- 5.1.3. Opportunities
  - 5.1.3.1. Innovations in the precision medicine and development of targeted therapies
  - 5.1.3.2. Designation of idiopathic pulmonary fibrosis as orphan disease and incentives to develop IPF drugs
- 5.1.4. Challenges
  - 5.1.4.1. Concerns associated with side-effects and potential risk of IPF treatment
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Idiopathic Pulmonary Fibrosis Market, by Drug Type

6.1. Introduction
6.2. Nintedanib
6.3. Pirfenidone

7. Idiopathic Pulmonary Fibrosis Market, by Distribution Channel

7.1. Introduction
7.2. Offline
7.3. Online

8. Idiopathic Pulmonary Fibrosis Market, by End-User

8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Home Care Facilities
8.4. Hospitals & Clinics

9. Americas Idiopathic Pulmonary Fibrosis Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Idiopathic Pulmonary Fibrosis Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Idiopathic Pulmonary Fibrosis Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
- 13.1.1. Algernon Pharmaceuticals Inc.
- 13.1.2. Alkem Laboratories Ltd.
- 13.1.3. AstraZeneca PLC
- 13.1.4. Avalyn Pharma Inc.
- 13.1.5. Biogen, Inc.
- 13.1.6. Boehringer Ingelheim International GmbH
- 13.1.7. Bristol Myers Squibb
- 13.1.8. Camber Pharmaceuticals, Inc. by Hetero Labs Limited
- 13.1.9. Chemo Healthcare Pvt. Ltd.
- 13.1.10. Cipla Limited
- 13.1.11. Dr Reddy's Laboratories Ltd.
- 13.1.12. FibroGen, Inc.
- 13.1.13. Galapagos NV
- 13.1.14. Glenmark Pharmaceuticals Ltd.
- 13.1.15. GNI Group Ltd.
- 13.1.16. Horizon Therapeutics PLC by Amgen Inc.
- 13.1.17. Lupin Ltd.
- 13.1.18. MediciNova, Inc.
- 13.1.19. Merck & Co.
- 13.1.20. Mission Therapeutics
- 13.1.21. MSN Laboratories Private Limited
- 13.1.22. Sandoz International GmbH
- 13.1.23. Sanify Healthcare Private Limited
- 13.1.24. Shionogi & Co., Ltd.
- 13.1.25. Teva Pharmaceuticals, Inc.
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing